<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388347</url>
  </required_header>
  <id_info>
    <org_study_id>D5450C00001</org_study_id>
    <nct_id>NCT02388347</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety of MEDI7836 in Healthy Adults.</brief_title>
  <official_title>A Phase 1a, Randomised, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI7836 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety of a single ascending dose of MEDI7836 in healthy adult male subjects
      and healthy adult female subjects of non-childbearing potential.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1a, randomised, blinded (the investigator and subject will be blinded to
      treatment assignment and sponsor will be unblinded to treatment assignment),
      placebo-controlled study to evaluate the safety of single-ascending SC doses of MEDI7836 in
      healthy adult males subjects and healthy adult female subjects of non-childbearing potential.
      The study will be conducted at a single site in the United Kingdom (UK). Four dosing cohorts
      of MEDI7836 or placebo are planned for this study for a total of 32 subjects (24 subjects
      receiving MEDI7836, 8 subjects receiving placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
    <description>Any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received MEDI7836. Treatment-emergent adverse events between administration of investigational product and Day 281 that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection Site Reactions</measure>
    <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
    <description>Participants were evaluated for manifestations of injection site reactions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events</measure>
    <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
    <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent adverse events between first dose of study drug and Day 281 after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs and Physical Examination Abnormalities Reported as Treatment-Emergent Adverse Events</measure>
    <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
    <description>Vital sign parameters included blood pressure, temperature, pulse rate, respiratory rate and weight. Physical examination included assessment of general appearance, weight, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, abdominal system, and nervous system. Criteria for abnormal physical findings was based on investigator's discretion. TEAEs were present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug until Day 281 after the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events</measure>
    <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
    <description>AEs observed in participants with clinically significant ECG abnormalities were assessed. ECG parameters included heart rate, RR, PR, QRS, QT and QTc intervals. Treatment-emergent adverse events between administration of investigational product and Day 281 that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI7836</measure>
    <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
    <description>Area under the concentration-time curve of the MEDI7836 in serum over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t]) of MEDI7836</measure>
    <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
    <description>Area under the concentration-time curve of the MEDI7836 in serum over the time interval from 0 to the last quantifiable data point (AUC0-t).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of MEDI7836</measure>
    <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
    <description>The Cmax is the maximum observed serum concentration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Systemic Clearance (CL/F) of MEDI7836</measure>
    <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Phase Elimination Half Life (T1/2) of MEDI7836</measure>
    <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
    <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI7836</measure>
    <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
    <description>The Tmax is defined as actual sampling time to reach maximum observed MEDI7836 concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal-Phase Volume of Distribution (Vz/F) of MEDI7836</measure>
    <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
    <description>The apparent volume of distribution of MEDI7836 after a single dose, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (Î»z).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Positive for Anti-Drug Antibodies to MEDI7836</measure>
    <time_frame>Predose on Day 1 to 281 days Postdose</time_frame>
    <description>A participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7836 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7836 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7836 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7836 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7836 Dose 1</intervention_name>
    <description>Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.</description>
    <arm_group_label>MEDI7836 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7836 Dose 2</intervention_name>
    <description>Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.</description>
    <arm_group_label>MEDI7836 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7836 Dose 3</intervention_name>
    <description>Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.</description>
    <arm_group_label>MEDI7836 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7836 Dose 4</intervention_name>
    <description>Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.</description>
    <arm_group_label>MEDI7836 Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Vital signs, ECG, and laboratory parameters within normal range at screening and Day
             -1

          2. Negative alcohol and drug screen at screening and Day -1

          3. Able and willing to comply with the requirements of the protocol

          4. Females subjects must have been surgically sterilised or be postmenopausal

          5. Nonsterilised males who are sexually active with a female partner of childbearing
             potential or a female partner who has been surgically sterilised by bilateral tubal
             ligation must use a condom with spermicide with their partner from screening until the
             end of the study follow-up period

        Exclusion Criteria:

          1. Concurrent enrolment in another clinical study where the subject is receiving an
             investigational product

          2. Individuals who are legally institutionalised

          3. Receipt of any marketed or investigational biologic agent within 4 months

          4. Receipt of any investigational non-biologic agent within 3 months or 5 half-lives
             prior to screening, whichever is longer

          5. Use of any medication (prescription or over the counter, including herbal remedies)
             within 14 days or 5 half-lives of Day 1,

          6. Known history of allergy or reaction to any component of the investigational product
             formulation

          7. History of anaphylaxis following any biologic therapy

          8. History of chronic alcohol or drug abuse within 12 months prior to screening,

          9. Presence of a positive drug or alcohol screen at screening and Day -1.

         10. Current smoker, or history of smoking within 6 months of screening

         11. Pregnant or breastfeeding women

         12. Any active medical or psychiatric condition or other reason which, in the opinion of
             the investigator or medical monitor, may compromise the safety of the subject in the
             study or interfere with evaluation of the investigational product or reduce the
             subject's ability to participate in the study

         13. Any clinically relevant abnormal findings in physical examination, ECG, vital signs,
             haematology, clinical chemistry or urinalysis during screening or Day -1,

         14. History of any known primary immunodeficiency disorder or use of immunosuppressive
             medication within 12 months of screening

         15. History of a clinically significant infection requiring antibiotics or antiviral
             medication from 30 days prior to screening, up to and including Day 1

         16. Diagnosis of a helminth parasitic infection within 6 months prior to screening that
             has not been treated with, or has failed to respond to, standard of care therapy

         17. History of cancer, except for basal cell carcinoma or in situ carcinoma of the cervix
             treated with apparent success with curative therapy â¥ 12 months prior to screening or
             other malignancies treated with apparent success with curative therapy â¥ 5 years prior
             to screening

         18. Positive tuberculosis (TB) test (Quantiferon-TB Gold) at screening or TB requiring
             treatment within the 12 months prior to the screening visit

         19. Positive hepatitis B surface antigen, hepatitis B anti-core antibody, or hepatitis C
             virus antibody serology at screening.

         20. Subjects with a history of hepatitis B vaccination without history of hepatitis B are
             allowed to enter the study.

         21. A positive human immunodeficiency virus test at screening or subject taking
             antiretroviral medications, as determined by medical history and/or subject's verbal
             report

         22. Evidence of active liver disease, including jaundice or aspartate transaminase (AST),
             alanine transaminase (ALT), or alkaline phosphatase greater than twice the upper limit
             of normal (ULN)

         23. Major surgery within 8 weeks prior to screening, or planed in-patient surgery or
             hospitalisation during the study period

         24. Receipt of live attenuated vaccines 30 days prior to the date of screening Where
             participation in the study would result in donation of blood or blood products in
             excess of 500 mL within an 8-week period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annelize Koch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <results_first_submitted>February 27, 2017</results_first_submitted>
  <results_first_submitted_qc>February 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2017</results_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 79 participants were screened. Of these, 32 participants were randomized and treated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>MEDI7836 Dose 1</title>
          <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>MEDI7836 Dose 2</title>
          <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>MEDI7836 Dose 3</title>
          <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>MEDI7836 Dose 4</title>
          <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>MEDI7836 Dose 1</title>
          <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>MEDI7836 Dose 2</title>
          <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>MEDI7836 Dose 3</title>
          <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>MEDI7836 Dose 4</title>
          <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.4" spread="9.9"/>
                    <measurement group_id="B2" value="38.2" spread="7.1"/>
                    <measurement group_id="B3" value="32.8" spread="11.5"/>
                    <measurement group_id="B4" value="32.8" spread="9.7"/>
                    <measurement group_id="B5" value="32.0" spread="14.0"/>
                    <measurement group_id="B6" value="34.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
        <description>Any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received MEDI7836. Treatment-emergent adverse events between administration of investigational product and Day 281 that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
        <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
          <description>Any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received MEDI7836. Treatment-emergent adverse events between administration of investigational product and Day 281 that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection Site Reactions</title>
        <description>Participants were evaluated for manifestations of injection site reactions.</description>
        <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
        <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection Site Reactions</title>
          <description>Participants were evaluated for manifestations of injection site reactions.</description>
          <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events</title>
        <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent adverse events between first dose of study drug and Day 281 after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.</description>
        <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
        <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events</title>
          <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent adverse events between first dose of study drug and Day 281 after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.</description>
          <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelet count decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transaminases increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs and Physical Examination Abnormalities Reported as Treatment-Emergent Adverse Events</title>
        <description>Vital sign parameters included blood pressure, temperature, pulse rate, respiratory rate and weight. Physical examination included assessment of general appearance, weight, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, abdominal system, and nervous system. Criteria for abnormal physical findings was based on investigator's discretion. TEAEs were present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug until Day 281 after the last dose of study drug.</description>
        <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
        <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs and Physical Examination Abnormalities Reported as Treatment-Emergent Adverse Events</title>
          <description>Vital sign parameters included blood pressure, temperature, pulse rate, respiratory rate and weight. Physical examination included assessment of general appearance, weight, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, abdominal system, and nervous system. Criteria for abnormal physical findings was based on investigator's discretion. TEAEs were present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug until Day 281 after the last dose of study drug.</description>
          <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events</title>
        <description>AEs observed in participants with clinically significant ECG abnormalities were assessed. ECG parameters included heart rate, RR, PR, QRS, QT and QTc intervals. Treatment-emergent adverse events between administration of investigational product and Day 281 that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
        <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment-Emergent Adverse Events</title>
          <description>AEs observed in participants with clinically significant ECG abnormalities were assessed. ECG parameters included heart rate, RR, PR, QRS, QT and QTc intervals. Treatment-emergent adverse events between administration of investigational product and Day 281 that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo.</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI7836</title>
        <description>Area under the concentration-time curve of the MEDI7836 in serum over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
        <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
        <population>Pharmacokinetic (PK) Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of MEDI7836</title>
          <description>Area under the concentration-time curve of the MEDI7836 in serum over the time interval from 0 extrapolated to infinity (AUC0-inf).</description>
          <population>Pharmacokinetic (PK) Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
          <units>Day*microgram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.958" spread="29.629"/>
                    <measurement group_id="O2" value="310.805" spread="204.858"/>
                    <measurement group_id="O3" value="807.725" spread="418.083"/>
                    <measurement group_id="O4" value="1101.742" spread="817.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t]) of MEDI7836</title>
        <description>Area under the concentration-time curve of the MEDI7836 in serum over the time interval from 0 to the last quantifiable data point (AUC0-t).</description>
        <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
        <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t]) of MEDI7836</title>
          <description>Area under the concentration-time curve of the MEDI7836 in serum over the time interval from 0 to the last quantifiable data point (AUC0-t).</description>
          <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
          <units>day*mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.106" spread="29.237"/>
                    <measurement group_id="O2" value="308.965" spread="203.367"/>
                    <measurement group_id="O3" value="799.769" spread="406.585"/>
                    <measurement group_id="O4" value="1096.620" spread="807.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of MEDI7836</title>
        <description>The Cmax is the maximum observed serum concentration of study drug.</description>
        <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
        <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of MEDI7836</title>
          <description>The Cmax is the maximum observed serum concentration of study drug.</description>
          <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.587" spread="0.436"/>
                    <measurement group_id="O2" value="10.435" spread="1.520"/>
                    <measurement group_id="O3" value="24.600" spread="5.313"/>
                    <measurement group_id="O4" value="41.933" spread="7.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Systemic Clearance (CL/F) of MEDI7836</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
        <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
        <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Systemic Clearance (CL/F) of MEDI7836</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
          <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
          <units>milliliter per day (mL/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616.206" spread="422.587"/>
                    <measurement group_id="O2" value="481.219" spread="282.488"/>
                    <measurement group_id="O3" value="463.827" spread="226.960"/>
                    <measurement group_id="O4" value="706.952" spread="283.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Phase Elimination Half Life (T1/2) of MEDI7836</title>
        <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.</description>
        <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
        <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Phase Elimination Half Life (T1/2) of MEDI7836</title>
          <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.</description>
          <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
          <units>day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.988" spread="14.902"/>
                    <measurement group_id="O2" value="28.091" spread="14.121"/>
                    <measurement group_id="O3" value="36.944" spread="9.329"/>
                    <measurement group_id="O4" value="37.013" spread="5.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI7836</title>
        <description>The Tmax is defined as actual sampling time to reach maximum observed MEDI7836 concentration.</description>
        <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
        <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI7836</title>
          <description>The Tmax is defined as actual sampling time to reach maximum observed MEDI7836 concentration.</description>
          <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
          <units>day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="4" upper_limit="15"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3" upper_limit="8"/>
                    <measurement group_id="O3" value="5.0" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O4" value="6.0" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal-Phase Volume of Distribution (Vz/F) of MEDI7836</title>
        <description>The apparent volume of distribution of MEDI7836 after a single dose, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (Î»z).</description>
        <time_frame>Predose on Day 1 and on Days 2, 3, 4, 6, 8, 10, 15, 29, 43, 57, 85, 113, 169, 225 and 281 Postdose</time_frame>
        <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal-Phase Volume of Distribution (Vz/F) of MEDI7836</title>
          <description>The apparent volume of distribution of MEDI7836 after a single dose, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (Î»z).</description>
          <population>PK Population included all participants who received MEDI7836 had detectable postdose MEDI7836 serum concentrations.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18885.105" spread="7689.663"/>
                    <measurement group_id="O2" value="15032.685" spread="6066.111"/>
                    <measurement group_id="O3" value="22930.365" spread="8180.111"/>
                    <measurement group_id="O4" value="36686.872" spread="14142.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Positive for Anti-Drug Antibodies to MEDI7836</title>
        <description>A participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.</description>
        <time_frame>Predose on Day 1 to 281 days Postdose</time_frame>
        <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo. Here, &quot;n&quot; is number of participants analysed at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7836 Dose 1</title>
            <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7836 Dose 2</title>
            <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7836 Dose 3</title>
            <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7836 Dose 4</title>
            <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Positive for Anti-Drug Antibodies to MEDI7836</title>
          <description>A participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.</description>
          <population>As Treated Population included all randomized participants and treated with MEDI7836 or placebo. Here, &quot;n&quot; is number of participants analysed at given time point.</population>
          <units>Percentage of participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=8,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Day 281 (n=8,6,5,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Study Drug Administration to 281 Days Postdose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received a single-dose of Placebo subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>MEDI7836 Dose 1</title>
          <description>Participants received a single-dose of MEDI7836 Dose 1 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MEDI7836 Dose 2</title>
          <description>Participants received a single-dose of MEDI7836 Dose 2 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>MEDI7836 Dose 3</title>
          <description>Participants received a single-dose of MEDI7836 Dose 3 subcutaneous (SC) injection on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MEDI7836 Dose 4</title>
          <description>Participants received a single-dose of MEDI7836 Dose 4 subcutaneous (SC) injection on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="11" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rene van der Merwe</name_or_title>
      <organization>MedImmune LLC</organization>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

